Literature DB >> 17188371

Pigment epithelium-derived factor in ulcerative colitis: possible relationship with disease activity.

Alicja Wiercinska-Drapalo1, Jerzy Jaroszewicz, Anna Parfieniuk, Tadeusz Wojciech Lapinski, Magdalena Rogalska, Danuta Prokopowicz.   

Abstract

OBJECTIVES: Pigment epithelium-derived factor (PEDF) is an endogenous most potential angiogenic inhibitor and increased expression of PEDF in intestinal mucosa specimens was shown in the course of ulcerative colitis (UC). The aim of the present study was to evaluate serum concentration of pigment epithelium-derived growth factor, a potent anti-angiogenic factor and its possible association with vascular endothelial growth factor (VEGF) levels and disease activity.
METHODS: Concentrations of PEDF and VEGF were measured in sera of 33 patients (13 females and 20 males) with active UC.
RESULTS: There was significant increase of serum PEDF (32.3+/-2.9 vs. 20.6+/-4.7 ng/mL, P<0.05) as well as VEGF (326.4+/-58.1 vs. 110.9+/-15.7 pg/mL, P<0.05) in UC patients compared to healthy controls. Serum PEDF showed strong, positive correlation with endoscopic score (r=0.622, P<0.001), while such association was absent in respect to VEGF (r=0.05, P=0.77). In contrast serum VEGF decreased in severe UC comparing to patients with a mild course of disease, however the difference was not significant (274.9+/-64.9 vs. 360.4+/-103.4 pg/mL, P=0.53).
CONCLUSIONS: Increase in serum PEDF during UC, especially in severe forms of disease suggests its involvement in UC pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188371     DOI: 10.1016/j.regpep.2006.11.006

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

1.  Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model.

Authors:  M L Broadhead; C R Dass; P F M Choong
Journal:  Br J Cancer       Date:  2011-10-06       Impact factor: 7.640

2.  Efficacy of continuously administered PEDF-derived synthetic peptides against osteosarcoma growth and metastasis.

Authors:  Matthew L Broadhead; Peter F M Choong; Crispin R Dass
Journal:  J Biomed Biotechnol       Date:  2012-05-30

3.  Role of anti-angiogenic factor endostatin in the pathogenesis of experimental ulcerative colitis.

Authors:  Ganna Tolstanova; Xiaoming Deng; Tetyana Khomenko; Pallavi Garg; Brankica Paunovic; Longchuan Chen; Shanthi V Sitaraman; Joseph Shiloach; Sandor Szabo; Zsuzsanna Sandor
Journal:  Life Sci       Date:  2010-11-01       Impact factor: 6.780

4.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06

Review 5.  Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review.

Authors:  Louiza Belkacemi; Shaun Xiaoliu Zhang
Journal:  J Exp Clin Cancer Res       Date:  2016-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.